2003
DOI: 10.1007/s00277-003-0608-2
|View full text |Cite
|
Sign up to set email alerts
|

Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

11
64
1
4

Year Published

2006
2006
2018
2018

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 142 publications
(80 citation statements)
references
References 19 publications
11
64
1
4
Order By: Relevance
“…Though there is a wide variation in TLS occurrence across the world, this result is comparable with previous researches that reported 26.5% and 30.7% incidence of TLS respectively [7, 8]. The LTLS and CTLS incidences were 11.5% and 18.0%; similar to 11.1% LTLS and 19.6% CTLS reported from a cohort study by Darmon et al [8] but differs from a report of lower incidence of CTLS (2.9%) in Iran and 6.7% in Saudi Arabia [9, 10].…”
Section: Discussionsupporting
confidence: 89%
“…Though there is a wide variation in TLS occurrence across the world, this result is comparable with previous researches that reported 26.5% and 30.7% incidence of TLS respectively [7, 8]. The LTLS and CTLS incidences were 11.5% and 18.0%; similar to 11.1% LTLS and 19.6% CTLS reported from a cohort study by Darmon et al [8] but differs from a report of lower incidence of CTLS (2.9%) in Iran and 6.7% in Saudi Arabia [9, 10].…”
Section: Discussionsupporting
confidence: 89%
“…More than 1 in 4 children with that malignancy will develop TLS after treatment. 4 Among adults, TLS is commonly seen after treatment for ALL, acute myeloid leukemia, and Burkitt’s lymphoma. 57 Although TLS is often associated with cytotoxic chemotherapy, reports exist of TLS occurring after treatment with radiation therapy, 8,9 dexamethasone treatment, 10 thalidomide therapy, 11,12 and with newer chemotherapeutic agents including bortezomib and rituximab.…”
Section: Epidemiologymentioning
confidence: 99%
“…As with other TLS models previously published (48, 49), our model may not be generalizable to other diseases and therapies. Rather than modeling a drug exposure-TLS relationship, which may change with each drug therapy, modeling of a biomarker-TLS relationship may be preferred, if such a biomarker could be identified to be rapidly modulated post flavopiridol therapy and correlate with TLS occurrence and either drug or metabolite levels.…”
Section: Discussionmentioning
confidence: 97%